Comparing tegoprazan and PPIs for treating H. pylori infection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the effectiveness of tegoprazan, a potassium-competitive acid blocker, compared to traditional proton pump inhibitors (PPIs) in eradicating Helicobacter pylori. The study focuses on assessing the eradication success rate and treatment compliance when using tegoprazan in combination with bismuth for first-line H. pylori treatment. The research is based on previous findings that suggest P-CABs like tegoprazan may improve patient compliance due to their dosing flexibility. The study will involve patients who can undergo gastroscopy and H. pylori testing.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Gastroscopy can be performed
* H. pylori test and pathological analysis can be performed

Exclusion Criteria:

* Age \< 20 or \> 80 years
* Anemia (serum hemoglobin level \< 10 g/dL)
* Severe systemic disease
* Advanced chronic liver disease
* Use of certain medications, including proton pump inhibitors, H2- receptor antagonists, or antibiotics
* History of H. pylori eradication
* Drug allergy to antibiotics
* History of gastric surgery
* Recent history of upper gastrointestinal bleeding

Where it's running

• Digestive Disease Center, Soonchunhyang University Hospital
  Seoul, South Korea Recruiting

Study contacts

• Principal investigator: Jun-Hyung Cho, M.D. — Soonchunhyang University Hospital
• Study coordinator: Jun-Hyung Cho
• Email: chojhmd@naver.com
• Phone: +82-2-709-9202

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining anti‑ulcer medicines with levofloxacin and amoxicillin to clear H. pylori infection

  This study will test whether giving adults one of three acid‑reducing drugs (Dexlansoprazole, Lansoprazole, or Vonoprazan) together with levofloxacin and amoxicillin for 14 days can clear H. pylori infection.

  Recruiting Phase 4 Dow University of Health Sciences · Karachi · NCT07344506

• Breath testing for gastric cancer screening

  This study is testing if breath tests can help find gastric cancer and related conditions in people who have cancer, precancerous lesions, or are at average risk.

  Recruiting at 3 sites University of Latvia · São Paulo and 4 other locations · NCT04022109

• Fecal transplant to help eradicate stubborn Helicobacter pylori infection

  This study tests whether giving a fecal microbiota transplant can help people with Helicobacter pylori infection that has not responded to standard treatments.

  Recruiting Phase 4 Sichuan Provincial People's Hospital · Chengdu, Sichuan · NCT07704255

• Fecal-guided simplified vonoprazan plus clarithromycin first-line therapy for H. pylori

  We are testing whether a two-drug regimen of vonoprazan plus clarithromycin clears H. pylori in adults whose fecal PCR shows no clarithromycin resistance mutations.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07439445

• Bismuth-amoxicillin-vonoprazan triple therapy versus bismuth-based quadruple therapy for H. pylori infection

  This will test whether a 14-day bismuth-amoxicillin-vonoprazan triple therapy works better and is as safe as a 14-day bismuth-based quadruple therapy for adults with H. pylori infection.

  Recruiting Kaohsiung Medical University · Kaohsiung City · NCT07358130

• P-CABs plus bismuth quadruple treatment for Helicobacter pylori infection

  This study tests whether using potassium-competitive acid blockers (P-CABs) in bismuth-containing quadruple therapy works better and is safe for adults with H. pylori infection.

  Recruiting Qilu Hospital of Shandong University · Jinan · NCT07285096

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.